C. Patel

Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan

A. Amin, J. Trocio, O. Dina, 2018, Journal of medical economics.

Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada

C. Baerwald, C. Nappi, D. Choquette, 2017, Rheumatology International.

How Useful Are Digital Health Terms for Outcomes Research? An ISPOR Special Interest Group Report.

J. R. Earla, K. Kolasa, V. Zah, 2022, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Abstract 19672: Comparison of Major-bleeding Risk and Health Care Costs Among Treatment-naïve Non-valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or Warfarin

A. Amin, O. Baser, J. Trocio, 2015 .

Incidence of dose escalation and impact on biologic costs among patients with rheumatoid arthritis treated with three intravenous agents.

David M. Smith, A. Nadkarni, C. Patel, 2017, Journal of comparative effectiveness research.

Budget Impact Analysis of Liposomal Amphotericin B and Amphotericin B Lipid Complex in the Treatment of Invasive Fungal Infections in the United States

D. Horn, Zheng-Yi Zhou, E. Wu, 2014, Applied Health Economics and Health Policy.

Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system

N. Rashid, A. Nadkarni, G. Aranda, 2016, Journal of medical economics.

The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis

K. Michaud, J. Shafrin, C. Patel, 2018, Journal of managed care & specialty pharmacy.

Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting

J. Trocio, H. Henk, J. Mardekian, 2018, Current medical research and opinion.

Clinical characteristics, healthcare costs, and resource utilization in hepatitis C vary by genotype

C. Blauer-Peterson, C. Patel, L. Rosenblatt, 2017, Current medical research and opinion.